首页 > 最新文献

Journal of Pharmacy Technology最新文献

英文 中文
Evaluating the Safety of Trough Versus Area Under the Curve (AUC)-Based Dosing Method of Vancomycin With Concomitant Piperacillin-Tazobactam. 评估万古霉素与哌拉西林-他唑巴坦并用时基于低谷给药法和基于曲线下面积(AUC)给药法的安全性
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 Epub Date: 2022-06-13 DOI: 10.1177/87551225221101736
Cassandra Karas, Kyle Manning, Darrell T Childress, Elizabeth W Covington, Melanie M Manis

Background: Vancomycin and piperacillin-tazobactam (VPT) is a common antibiotic combination used in hospitals, and there has been increasing data indicating that the combination is associated with increased rates of acute kidney injury (AKI). It is unclear if the dosing method of vancomycin would mitigate the risk of AKI seen with VPT. Objective: To observe and compare incidence of AKI in patients on VPT when using the trough-based dosing method versus the area-under-the-curve (AUC)-based dosing method. Methods: This was a multi-center, retrospective, observational study at 3 community hospitals. Adults receiving at least 48 hours of VPT were included. Patients with severe renal dysfunction, pregnant patients, prisoners, and patients with central nervous system infections, or malignancy were excluded. The primary outcome was incidence of AKI as defined by the Infectious Disease Society of America (IDSA) criteria. Results: A total of 300 patients were included in the study; 150 patients in both the trough and AUC groups. A total of 23 patients (15%) in the trough group and 17 patients (11%) in the AUC group met the primary outcome (odds ratio [OR]: 0.7058, 95% confidence interval [CI]: [0.3603, 1.3826], P = .3098). Conclusion and Relevance: The incidence of AKI was lower in the AUC group compared with the trough group; however, this was not significant. The results of our study suggest that there is no difference between incidence of AKI when using trough- or AUC-based dosing in those receiving VPT. Because of the small sample size and retrospective nature of the study, more data are needed.

背景:万古霉素和哌拉西林-他唑巴坦(VPT)是医院常用的抗生素组合,越来越多的数据表明,这种组合与急性肾损伤(AKI)发生率增加有关。目前尚不清楚万古霉素的给药方法是否能减轻 VPT 引起急性肾损伤的风险。目的观察并比较使用 VPT 的患者在使用基于谷值的给药方法和基于曲线下面积 (AUC) 的给药方法时的 AKI 发生率。方法:这是一项在 3 家社区医院进行的多中心、回顾性观察研究。研究对象包括接受至少 48 小时 VPT 治疗的成人。严重肾功能障碍患者、孕妇、囚犯、中枢神经系统感染患者或恶性肿瘤患者除外。主要结果是美国传染病学会(IDSA)标准定义的 AKI 发生率。结果:共有 300 名患者参与了研究;其中 150 名患者分属低谷组和 AUC 组。共有 23 名(15%)谷值组患者和 17 名(11%)AUC 组患者达到了主要结果(几率比 [OR]:0.7058,95% 置信度):0.7058,95% 置信区间 [CI]:[0.3603, 1.3826], P = .3098).结论与意义:与谷值组相比,AUC 组的 AKI 发生率较低;但差异并不显著。我们的研究结果表明,在接受 VPT 治疗的患者中,使用基于谷值或 AUC 的剂量时,AKI 发生率没有差异。由于样本量较小,且研究具有回顾性,因此还需要更多数据。
{"title":"Evaluating the Safety of Trough Versus Area Under the Curve (AUC)-Based Dosing Method of Vancomycin With Concomitant Piperacillin-Tazobactam.","authors":"Cassandra Karas, Kyle Manning, Darrell T Childress, Elizabeth W Covington, Melanie M Manis","doi":"10.1177/87551225221101736","DOIUrl":"10.1177/87551225221101736","url":null,"abstract":"<p><p><b>Background:</b> Vancomycin and piperacillin-tazobactam (VPT) is a common antibiotic combination used in hospitals, and there has been increasing data indicating that the combination is associated with increased rates of acute kidney injury (AKI). It is unclear if the dosing method of vancomycin would mitigate the risk of AKI seen with VPT. <b>Objective</b>: To observe and compare incidence of AKI in patients on VPT when using the trough-based dosing method versus the area-under-the-curve (AUC)-based dosing method. <b>Methods</b>: This was a multi-center, retrospective, observational study at 3 community hospitals. Adults receiving at least 48 hours of VPT were included. Patients with severe renal dysfunction, pregnant patients, prisoners, and patients with central nervous system infections, or malignancy were excluded. The primary outcome was incidence of AKI as defined by the Infectious Disease Society of America (IDSA) criteria. <b>Results:</b> A total of 300 patients were included in the study; 150 patients in both the trough and AUC groups. A total of 23 patients (15%) in the trough group and 17 patients (11%) in the AUC group met the primary outcome (odds ratio [OR]: 0.7058, 95% confidence interval [CI]: [0.3603, 1.3826], <i>P</i> = .3098). <b>Conclusion and Relevance</b>: The incidence of AKI was lower in the AUC group compared with the trough group; however, this was not significant. The results of our study suggest that there is no difference between incidence of AKI when using trough- or AUC-based dosing in those receiving VPT. Because of the small sample size and retrospective nature of the study, more data are needed.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272489/pdf/10.1177_87551225221101736.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9622058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Once-Weekly Semaglutide for Weight Management: A Clinical Review. 每周一次的西马鲁肽用于体重管理:临床回顾。
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-08-01 DOI: 10.1177/87551225221092681
Abby Fornes, Jamie Huff, Roger Iain Pritchard, Miranda Godfrey

Objective: To review the efficacy, safety, and role of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide for chronic weight management. Data Sources: A literature search of PubMed/MEDLINE and Google Scholar was performed using the search terms: semaglutide 2.4, weight, and obesity. Ongoing studies of semaglutide were identified utilizing clinicaltrials.gov. Study Selection and Data Extraction: All English-language articles evaluating the efficacy and safety of semaglutide 2.4 mg for weight management in humans were included. Data Synthesis: Once-weekly injectable semaglutide 2.4 mg is indicated as an adjunct to a reduced-calorie diet and increased exercise for chronic weight management in adults with a body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Semaglutide 2.4 mg has consistently demonstrated clinically significant weight loss across all phase 3 STEP (semaglutide treatment effect in people with obesity) trials, and long-term efficacy and safety have been confirmed for up to 2 years. Gastrointestinal side effects were the most frequently reported side effects, including nausea, vomiting, constipation, and diarrhea. Safety data for semaglutide 2.4 mg were consistent with that reported previously for the GLP-1 receptor agonist class. Conclusions: Semaglutide 2.4 mg is a highly efficacious agent for weight management, with a safety profile similar to that of other GLP-1 receptor agonists. It is a feasible option for chronic weight management, with data for up to 2 years. It is currently the only once-weekly weight loss medication, although cost may limit its utilization.

目的:综述胰高血糖素样肽-1 (GLP-1)受体激动剂semaglutide在慢性体重控制中的疗效、安全性和作用。数据来源:检索PubMed/MEDLINE和Google Scholar的文献,检索词为:semaglutide 2.4, weight, and obesity。正在进行的西马鲁肽研究是通过临床试验网站确定的。研究选择和数据提取:纳入了所有评价semaglutide 2.4 mg用于人类体重管理的有效性和安全性的英文文章。数据综合:对于体重指数(BMI)≥30 kg/m2或≥27 kg/m2且伴有至少一种体重相关合并症(如高血压、2型糖尿病或血脂异常)的成年人,每周一次注射西马鲁肽2.4 mg作为减少卡路里饮食和增加运动的辅助治疗。Semaglutide 2.4 mg在所有3期STEP (Semaglutide治疗肥胖症患者的效果)试验中一致显示出临床显着的体重减轻,并且长期疗效和安全性已被证实长达2年。胃肠道副作用是最常见的副作用,包括恶心、呕吐、便秘和腹泻。semaglutide 2.4 mg的安全性数据与先前报道的GLP-1受体激动剂类一致。结论:Semaglutide 2.4 mg是一种非常有效的体重管理药物,其安全性与其他GLP-1受体激动剂相似。对于慢性体重管理来说,这是一个可行的选择,数据长达2年。它是目前唯一一种每周一次的减肥药,尽管成本可能限制了它的使用。
{"title":"Once-Weekly Semaglutide for Weight Management: A Clinical Review.","authors":"Abby Fornes,&nbsp;Jamie Huff,&nbsp;Roger Iain Pritchard,&nbsp;Miranda Godfrey","doi":"10.1177/87551225221092681","DOIUrl":"https://doi.org/10.1177/87551225221092681","url":null,"abstract":"<p><p><b>Objective:</b> To review the efficacy, safety, and role of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide for chronic weight management. <b>Data Sources:</b> A literature search of PubMed/MEDLINE and Google Scholar was performed using the search terms: semaglutide 2.4, weight, and obesity. Ongoing studies of semaglutide were identified utilizing clinicaltrials.gov. <b>Study Selection and Data Extraction:</b> All English-language articles evaluating the efficacy and safety of semaglutide 2.4 mg for weight management in humans were included. <b>Data Synthesis:</b> Once-weekly injectable semaglutide 2.4 mg is indicated as an adjunct to a reduced-calorie diet and increased exercise for chronic weight management in adults with a body mass index (BMI) ≥30 kg/m<sup>2</sup> or ≥27 kg/m<sup>2</sup> with at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Semaglutide 2.4 mg has consistently demonstrated clinically significant weight loss across all phase 3 STEP (semaglutide treatment effect in people with obesity) trials, and long-term efficacy and safety have been confirmed for up to 2 years. Gastrointestinal side effects were the most frequently reported side effects, including nausea, vomiting, constipation, and diarrhea. Safety data for semaglutide 2.4 mg were consistent with that reported previously for the GLP-1 receptor agonist class. <b>Conclusions:</b> Semaglutide 2.4 mg is a highly efficacious agent for weight management, with a safety profile similar to that of other GLP-1 receptor agonists. It is a feasible option for chronic weight management, with data for up to 2 years. It is currently the only once-weekly weight loss medication, although cost may limit its utilization.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272494/pdf/10.1177_87551225221092681.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9451332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
A Reappraisal of Oxandrolone in Burn Management. 重新评估 Oxandrolone 在烧伤治疗中的作用。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-01 Epub Date: 2022-05-03 DOI: 10.1177/87551225221091115
Jonathan Kopel, Grant Sorensen, John Griswold

Objective: Burn injuries remain among the most severe traumatic injuries globally. With the discovery of cortisol, the use of steroids has become an essential therapy for the management of inflammatory and metabolic conditions. Several studies have shown the steroid oxandrolone improves burn injuries through stimulating anabolic and reducing catabolic processes. In this review, we examine the efficacy and applications of oxandrolone with regard to burn management and treatment. Data Sources: A literature search was performed using the PubMed database from January 1990 to May 2020 to identify articles on oxandrolone and burn management. A total of 18 studies were included in our review. Study Selection and Criteria: The keywords used in our search strategy for PubMed included "oxandrolone" and "burns." Data Synthesis: The main benefit of oxandrolone is the improved long-term lean body, protein, and bone mineral mass of burn patients. In addition, 3 separate meta-analyses showed oxandrolone shortened length of hospital stay, donor-site healing time, reduced weight loss, and net protein loss. However, oxandrolone therapy did not affect mortality, infection, or liver function. Conclusion: Oxandrolone remains an effective therapy for reducing the hypermetabolic response and comorbidities from burn injuries. Future clinical trials are needed using larger sample sizes and long-term follow-up to determine whether oxandrolone in the context of rehabilitation programs can reduce mortality, lower treatment costs, and improve function outcomes among burn patients.

目的:烧伤仍然是全球最严重的创伤之一。随着皮质醇的发现,使用类固醇已成为治疗炎症和新陈代谢疾病的重要疗法。多项研究表明,类固醇氧诺龙可通过刺激合成代谢和减少分解代谢过程来改善烧伤。在这篇综述中,我们将探讨氧诺龙在烧伤管理和治疗方面的功效和应用。数据来源:我们使用 PubMed 数据库对 1990 年 1 月至 2020 年 5 月期间的文献进行了搜索,以确定有关氧杂蒽酮和烧伤管理的文章。共有 18 项研究被纳入我们的综述。研究选择和标准:我们在 PubMed 搜索策略中使用的关键词包括 "奥昔诺龙 "和 "烧伤"。数据综合:奥昔诺龙的主要益处在于改善烧伤患者的长期瘦身、蛋白质和骨矿物质含量。此外,3 项独立的荟萃分析表明,奥昔诺龙缩短了住院时间、供体部位愈合时间,减少了体重减轻和蛋白质净损失。不过,奥昔诺龙疗法不会影响死亡率、感染或肝功能。结论奥昔诺龙仍然是减少烧伤引起的高代谢反应和合并症的有效疗法。未来的临床试验需要使用更大的样本量和长期随访,以确定在康复计划中使用奥昔诺龙是否能降低烧伤患者的死亡率、降低治疗成本并改善其功能。
{"title":"A Reappraisal of Oxandrolone in Burn Management.","authors":"Jonathan Kopel, Grant Sorensen, John Griswold","doi":"10.1177/87551225221091115","DOIUrl":"10.1177/87551225221091115","url":null,"abstract":"<p><p><b>Objective:</b> Burn injuries remain among the most severe traumatic injuries globally. With the discovery of cortisol, the use of steroids has become an essential therapy for the management of inflammatory and metabolic conditions. Several studies have shown the steroid oxandrolone improves burn injuries through stimulating anabolic and reducing catabolic processes. In this review, we examine the efficacy and applications of oxandrolone with regard to burn management and treatment. <b>Data Sources:</b> A literature search was performed using the PubMed database from January 1990 to May 2020 to identify articles on oxandrolone and burn management. A total of 18 studies were included in our review. <b>Study Selection and Criteria:</b> The keywords used in our search strategy for PubMed included \"oxandrolone\" and \"burns.\" <b>Data Synthesis:</b> The main benefit of oxandrolone is the improved long-term lean body, protein, and bone mineral mass of burn patients. In addition, 3 separate meta-analyses showed oxandrolone shortened length of hospital stay, donor-site healing time, reduced weight loss, and net protein loss. However, oxandrolone therapy did not affect mortality, infection, or liver function. <b>Conclusion:</b> Oxandrolone remains an effective therapy for reducing the hypermetabolic response and comorbidities from burn injuries. Future clinical trials are needed using larger sample sizes and long-term follow-up to determine whether oxandrolone in the context of rehabilitation programs can reduce mortality, lower treatment costs, and improve function outcomes among burn patients.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272491/pdf/10.1177_87551225221091115.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9457792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationships Between Remote Asynchronous Lectures and Summative Assessment Performance in four Pharmacotherapeutics Courses. 四门药物治疗学课程远程异步授课与总结性考核绩效的关系
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-08-01 DOI: 10.1177/87551225221092683
Jordan Sedlacek, Paul M Boylan, Antonio Perry

Background: Synchronous education describes when teaching, learning, and assessment occur concurrently and asynchronous education describes when teaching, learning, and assessment occur anytime. Remote learning is where teaching and learning occur via technological means. Objective: This report describes a remote, asynchronous learning method implemented in a 3-year, block curriculum, Doctor of Pharmacy degree program. Methods: Remote asynchronous lectures embedded with quizzes were delivered to pharmacy students at the end of their first professional year and beginning of their second professional year. Camtasia software and Screencast.com were utilized during portions of 4 pharmacotherapeutic-based courses. Students completed time-spaced quizzes embedded every 5 to 15 minutes throughout the videos and quiz scores were recorded. Discrete watches, number of total watches, and average number of video quiz questions correctly answered were examined for Spearman's rank correlation coefficient (ρ) with end-of-course summative assessment scores. Results: There were no strong positive correlations between discrete watches, number of total watches, and average number of video quiz questions correctly answered and end-of-course assessment scores (ρ range: -0.47 to 0.25). There were weak to moderate correlations within the rheumatology and dermatology assessment scores based on the Screencast.com content questions and the number of unique video watches (ρ = 0.40), average number of total video watches (ρ = 0.28), and average percent of quiz questions correct (ρ = 0.40), all of which were statistically significant (P < 0.05). Conclusions: Remote asynchronous lectures including time-spaced quizzes were not associated with improvements in summative assessment performance. Mild positive correlations between remote asynchronous lectures and time-spaced quizzes may correspond with discrete questions on a summative assessment but those relationships may be influenced by the content within the remote asynchronous lectures.

背景:同步教育描述的是教学、学习和评估同时发生的情况,异步教育描述的是教学、学习和评估随时发生的情况。远程学习是通过技术手段进行教学和学习的地方。目的:本报告描述了一种远程,异步学习方法在3年,块课程,药学博士学位课程实施。方法:在药学专业一年级结束和二年级开始时,对药学专业学生进行远程异步授课,并辅以小测验。在4个以药物治疗为基础的课程中使用Camtasia软件和Screencast.com。在整个视频中,学生们每隔5到15分钟完成一次定时测试,测试分数被记录下来。对离散手表、总手表数和正确回答视频测验问题的平均数量进行Spearman等级相关系数(ρ)与课程结束总结性评估分数的检验。结果:离散手表、总手表数、平均正确回答视频测验问题数与课程结束评估分数之间无强正相关(ρ范围:-0.47至0.25)。基于Screencast.com内容问题的风湿病学和皮肤病学评估分数与唯一视频观看次数(ρ = 0.40)、平均总视频观看次数(ρ = 0.28)和平均测试问题正确率(ρ = 0.40)之间存在弱至中度相关性,均具有统计学意义(P < 0.05)。结论:包括时间间隔测验在内的远程异步讲座与总结性评估成绩的改善无关。远程异步讲座和时间间隔测验之间的轻微正相关可能与总结性评估中的离散问题相对应,但这些关系可能受到远程异步讲座内容的影响。
{"title":"Relationships Between Remote Asynchronous Lectures and Summative Assessment Performance in four Pharmacotherapeutics Courses.","authors":"Jordan Sedlacek,&nbsp;Paul M Boylan,&nbsp;Antonio Perry","doi":"10.1177/87551225221092683","DOIUrl":"https://doi.org/10.1177/87551225221092683","url":null,"abstract":"<p><p><b>Background:</b> Synchronous education describes when teaching, learning, and assessment occur concurrently and asynchronous education describes when teaching, learning, and assessment occur anytime. Remote learning is where teaching and learning occur via technological means. <b>Objective:</b> This report describes a remote, asynchronous learning method implemented in a 3-year, block curriculum, Doctor of Pharmacy degree program. <b>Methods:</b> Remote asynchronous lectures embedded with quizzes were delivered to pharmacy students at the end of their first professional year and beginning of their second professional year. Camtasia software and Screencast.com were utilized during portions of 4 pharmacotherapeutic-based courses. Students completed time-spaced quizzes embedded every 5 to 15 minutes throughout the videos and quiz scores were recorded. Discrete watches, number of total watches, and average number of video quiz questions correctly answered were examined for Spearman's rank correlation coefficient (ρ) with end-of-course summative assessment scores. <b>Results:</b> There were no strong positive correlations between discrete watches, number of total watches, and average number of video quiz questions correctly answered and end-of-course assessment scores (ρ range: -0.47 to 0.25). There were weak to moderate correlations within the rheumatology and dermatology assessment scores based on the Screencast.com content questions and the number of unique video watches (ρ = 0.40), average number of total video watches (ρ = 0.28), and average percent of quiz questions correct (ρ = 0.40), all of which were statistically significant (<i>P</i> < 0.05). <b>Conclusions:</b> Remote asynchronous lectures including time-spaced quizzes were not associated with improvements in summative assessment performance. Mild positive correlations between remote asynchronous lectures and time-spaced quizzes may correspond with discrete questions on a summative assessment but those relationships may be influenced by the content within the remote asynchronous lectures.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272492/pdf/10.1177_87551225221092683.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10014242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Multiorgan Failure After Phentermine Overdose. 芬特明过量后多器官衰竭。
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-01 DOI: 10.1177/87551225221088980
Gia Thinh D Truong, Zachary A Creech, Shraddha Narechania, Mark A Malesker
Phentermine is the most prescribed anorexiant in the United States. There is a paucity of literature on consequences of phentermine overdose.1 We present a case of multiorgan failure secondary to phentermine self-overdose in an elderly male. A 69-year-old man with a history of epilepsy, major depressive disorder, prior methamphetamine abuse, schizophrenia, suicidal ideation, and cerebrovascular accident presented to the emergency department following intentional overdose of approximately 750 mg of phentermine. His home medications included quetiapine, aspirin, lisinopril, and phentermine. Urine drug analysis was positive for amphetamines, tricyclics, and bupropion. Acetaminophen, salicylate, and alcohol were not detected in the toxicology screen. A phentermine blood level was not ordered. Upon presentation, the patient was alert and able to follow commands while endorsing excessive muscle twitching and spastic movements. Vital signs upon presentation revealed a temperature of 36.7°C, heart rate of 135 beats/minute, respiratory rate of 24 breaths/minute, blood pressure of 185/125 mm Hg, and oxygen saturation of 94% on room air. He was tachycardic, tachypneic, and hypertensive. An electrocardiogram demonstrated atrial fibrillation followed by regular, narrow complex supraventricular tachycardia with a right bundle branch block. Atelectasis was seen in the left lung base. Initial labs were significant for leukocytosis, acute kidney injury, rhabdomyolysis, metabolic acidosis, and transaminitis. Computed tomography of the head and chest was unremarkable. An echocardiogram revealed an ejection fraction of 10% to 15%, akinetic apex, and multiple areas of hypokinesis consistent with stress cardiomyopathy. He subsequently became more agitated requiring intubation and ICU admission. Emergent hemodialysis was required given worsening acidosis, kidney injury, hyperkalemia, and rhabdomyolysis. The patient also received brief use of vasopressors. The creatine kinase peaked at 14 000 U/L, and troponin concentration peaked at 38 ng/mL before trending down. The patient’s acute renal failure and anion gap metabolic acidosis were corrected after 2 rounds of dialysis. He was extubated after 5 days of ventilation. On day 11, the patient was discharged to a skilled nursing facility. Phentermine is a centrally acting sympathomimetic amine that suppresses appetite and assists with short-term weight loss.1 Phentermine has a high potential of misuse. Adverse effects of tachycardia, decreased visual acuity, nausea, sleeplessness, anxiety, psychosis, and manic-like episodes are linked with phentermine therapy.2 Cardiac complications can arise due to enhanced AV nodal conduction effects from a similar structure to amphetamine.3 Case reports have described the development of prolonged QT interval and polymorphic ventricular tachycardia, supraventricular tachycardia, and recurrent ventricular fibrillation with cardiac vasospasm.3 One case report described the onset of rhabdomy
{"title":"Multiorgan Failure After Phentermine Overdose.","authors":"Gia Thinh D Truong,&nbsp;Zachary A Creech,&nbsp;Shraddha Narechania,&nbsp;Mark A Malesker","doi":"10.1177/87551225221088980","DOIUrl":"https://doi.org/10.1177/87551225221088980","url":null,"abstract":"Phentermine is the most prescribed anorexiant in the United States. There is a paucity of literature on consequences of phentermine overdose.1 We present a case of multiorgan failure secondary to phentermine self-overdose in an elderly male. A 69-year-old man with a history of epilepsy, major depressive disorder, prior methamphetamine abuse, schizophrenia, suicidal ideation, and cerebrovascular accident presented to the emergency department following intentional overdose of approximately 750 mg of phentermine. His home medications included quetiapine, aspirin, lisinopril, and phentermine. Urine drug analysis was positive for amphetamines, tricyclics, and bupropion. Acetaminophen, salicylate, and alcohol were not detected in the toxicology screen. A phentermine blood level was not ordered. Upon presentation, the patient was alert and able to follow commands while endorsing excessive muscle twitching and spastic movements. Vital signs upon presentation revealed a temperature of 36.7°C, heart rate of 135 beats/minute, respiratory rate of 24 breaths/minute, blood pressure of 185/125 mm Hg, and oxygen saturation of 94% on room air. He was tachycardic, tachypneic, and hypertensive. An electrocardiogram demonstrated atrial fibrillation followed by regular, narrow complex supraventricular tachycardia with a right bundle branch block. Atelectasis was seen in the left lung base. Initial labs were significant for leukocytosis, acute kidney injury, rhabdomyolysis, metabolic acidosis, and transaminitis. Computed tomography of the head and chest was unremarkable. An echocardiogram revealed an ejection fraction of 10% to 15%, akinetic apex, and multiple areas of hypokinesis consistent with stress cardiomyopathy. He subsequently became more agitated requiring intubation and ICU admission. Emergent hemodialysis was required given worsening acidosis, kidney injury, hyperkalemia, and rhabdomyolysis. The patient also received brief use of vasopressors. The creatine kinase peaked at 14 000 U/L, and troponin concentration peaked at 38 ng/mL before trending down. The patient’s acute renal failure and anion gap metabolic acidosis were corrected after 2 rounds of dialysis. He was extubated after 5 days of ventilation. On day 11, the patient was discharged to a skilled nursing facility. Phentermine is a centrally acting sympathomimetic amine that suppresses appetite and assists with short-term weight loss.1 Phentermine has a high potential of misuse. Adverse effects of tachycardia, decreased visual acuity, nausea, sleeplessness, anxiety, psychosis, and manic-like episodes are linked with phentermine therapy.2 Cardiac complications can arise due to enhanced AV nodal conduction effects from a similar structure to amphetamine.3 Case reports have described the development of prolonged QT interval and polymorphic ventricular tachycardia, supraventricular tachycardia, and recurrent ventricular fibrillation with cardiac vasospasm.3 One case report described the onset of rhabdomy","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116121/pdf/10.1177_87551225221088980.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9418434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prescribing Patterns of Antihypertensive Agents and Blood Pressure Control Among Patients With Incident Stage 2 Hypertension. 降压药处方模式与2期高血压患者血压控制
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-01 DOI: 10.1177/87551225211069802
Micah V Helms, Ashley L Edwards, Taylor H Suszynsky, Andrew Y Hwang

Background: Initiation of appropriate antihypertensive therapy is crucial, particularly among patients with stage 2 hypertension, whom initiation of dual antihypertensive agents is suggested. Little is known regarding real-world prescribing of antihypertensive agents for patients with incident stage 2 hypertension. Objective: The primary objective was to describe prescribing patterns of antihypertensive therapy among patients with incident stage 2 hypertension. The secondary objectives included determining association of blood pressure (BP) control with initial multiple antihypertensive agents. Methods: Retrospective cohort analysis was conducted using electronic medical records from 6 primary care clinics between January 2014 and June 2019. Included patients were ≥18 years with an initial diagnosis of stage 2 hypertension, defined as BP ≥160/100 mm Hg Primary analysis was characterizing prescribing patterns of antihypertensive agents among patients with incident stage 2 hypertension. Investigation of BP control (<140/90 mm Hg) at 3 months of diagnosis was also performed. Results: We identified 261 patients with incident stage 2 hypertension (mean age, 52 years; 53.2% males; mean baseline BP, 162.1/100.1 mm Hg). Approximately 72% of patients were initiated on single antihypertensive agent, with the most common being angiotensin receptor blockers (ARBs; 25.7%) and angiotensin-converting-enzyme (ACE) inhibitors (24.6%). Commonly initiated multiple antihypertensive agents were ACE-inhibitor + thiazide-like diuretic (52.7%), followed by an ARB + thiazide-like diuretic (21.6%). Multiple antihypertensive therapy was associated with improved BP control at 3 months (adjusted odds ratio [OR], 3.54; 95% confidence interval [CI], 1.55-8.06). Conclusion: Majority of patients with incident stage 2 hypertension were prescribed initial single antihypertensive therapy, though better BP control at 3 months was seen among those initiated on multi-antihypertensive therapy.

背景:开始适当的降压治疗是至关重要的,特别是在2期高血压患者中,建议开始使用双重降压药物。对于2期高血压患者的实际降压药处方了解甚少。目的:主要目的是描述2期高血压患者抗高血压治疗的处方模式。次要目的包括确定血压(BP)控制与初始多种抗高血压药物的关系。方法:利用2014年1月至2019年6月期间6家初级保健诊所的电子病历进行回顾性队列分析。纳入的患者年龄≥18岁,初始诊断为2期高血压,定义为血压≥160/100 mm Hg,主要分析2期高血压患者抗高血压药物的处方模式。调查血压控制(结果:我们确定了261例2期高血压患者(平均年龄52岁;男性53.2%;平均基线血压,162.1/100.1 mm Hg)。大约72%的患者开始使用单一抗高血压药物,最常见的是血管紧张素受体阻滞剂(ARBs;25.7%)和血管紧张素转换酶(ACE)抑制剂(24.6%)。常用的多种降压药物是ace抑制剂+噻嗪类利尿剂(52.7%),其次是ARB +噻嗪类利尿剂(21.6%)。多重抗高血压治疗与3个月时血压控制改善相关(校正优势比[OR], 3.54;95%可信区间[CI], 1.55-8.06)。结论:大多数2期高血压患者最初只接受单一降压治疗,但在开始接受多种降压治疗的患者中,3个月时血压控制较好。
{"title":"Prescribing Patterns of Antihypertensive Agents and Blood Pressure Control Among Patients With Incident Stage 2 Hypertension.","authors":"Micah V Helms,&nbsp;Ashley L Edwards,&nbsp;Taylor H Suszynsky,&nbsp;Andrew Y Hwang","doi":"10.1177/87551225211069802","DOIUrl":"https://doi.org/10.1177/87551225211069802","url":null,"abstract":"<p><p><b>Background:</b> Initiation of appropriate antihypertensive therapy is crucial, particularly among patients with stage 2 hypertension, whom initiation of dual antihypertensive agents is suggested. Little is known regarding real-world prescribing of antihypertensive agents for patients with incident stage 2 hypertension. <b>Objective:</b> The primary objective was to describe prescribing patterns of antihypertensive therapy among patients with incident stage 2 hypertension. The secondary objectives included determining association of blood pressure (BP) control with initial multiple antihypertensive agents. <b>Methods:</b> Retrospective cohort analysis was conducted using electronic medical records from 6 primary care clinics between January 2014 and June 2019. Included patients were ≥18 years with an initial diagnosis of stage 2 hypertension, defined as BP ≥160/100 mm Hg Primary analysis was characterizing prescribing patterns of antihypertensive agents among patients with incident stage 2 hypertension. Investigation of BP control (<140/90 mm Hg) at 3 months of diagnosis was also performed. <b>Results:</b> We identified 261 patients with incident stage 2 hypertension (mean age, 52 years; 53.2% males; mean baseline BP, 162.1/100.1 mm Hg). Approximately 72% of patients were initiated on single antihypertensive agent, with the most common being angiotensin receptor blockers (ARBs; 25.7%) and angiotensin-converting-enzyme (ACE) inhibitors (24.6%). Commonly initiated multiple antihypertensive agents were ACE-inhibitor + thiazide-like diuretic (52.7%), followed by an ARB + thiazide-like diuretic (21.6%). Multiple antihypertensive therapy was associated with improved BP control at 3 months (adjusted odds ratio [OR], 3.54; 95% confidence interval [CI], 1.55-8.06). <b>Conclusion:</b> Majority of patients with incident stage 2 hypertension were prescribed initial single antihypertensive therapy, though better BP control at 3 months was seen among those initiated on multi-antihypertensive therapy.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116125/pdf/10.1177_87551225211069802.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10624644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential Drug Interactions Between Psychotropics and Intravenous Chemotherapeutics Used by Patients With Cancer. 癌症患者使用的精神药物和静脉化疗药物之间潜在的药物相互作用。
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-01 DOI: 10.1177/87551225211073942
Eric Diego Turossi-Amorim, Bruna Camargo, Diego Zapelini do Nascimento, Fabiana Schuelter-Trevisol

Introduction: Patients undergoing cancer treatment usually have comorbidities, and psychiatric disorders are commonly seen in these patients. For the treatment of these psychiatric disorders, the use of psychotropic drugs is common, turning these patients susceptible to untoward drug interactions. Therefore, the aim of this study was to estimate the prevalence of clinically relevant drug-drug interactions (DDI) between chemotherapeutic and psychotropic agents in patients with cancer treated at an oncology service in southern Brazil. Methods: An observational epidemiological study with a cross-sectional census-type design was carried out between October and December 2020. The drug-drug interactions were identified through consultation and analysis of the Medscape Drug Interaction Check and Micromedex databases. The interactions were classified as major, when the interaction can be fatal and/or require medical intervention to avoid or minimize serious adverse effects and moderate, when the interaction can exacerbate the patient's condition and/or requires changes in therapy. Results: A total of 74 patients was included in the study among the 194 patients seen in the oncology service during the period studied. A total of 24 (32.4%) DDIs were found, 21 (87.5%) of which were classified as being of major risk and 3 (12.5%) as moderate risk. According to the mechanism of action, 19 (79.1%) were classified as pharmacodynamic interactions and 5 (20.9%) as pharmacokinetic interactions. Conclusion: It was shown that a considerable percentage of patients undergoing intravenous chemotherapy are at risk of pharmacological interaction with psychotropic drugs. Thus, it is essential that the oncologist considers all psychotropic drugs and other drugs used by patients in order to avoid drug-drug interactions.

导读:接受癌症治疗的患者通常有合并症,精神疾病在这些患者中很常见。对于这些精神疾病的治疗,使用精神药物是常见的,使这些患者易受不良药物相互作用的影响。因此,本研究的目的是估计在巴西南部肿瘤服务中心接受治疗的癌症患者中化疗药物和精神药物之间临床相关药物-药物相互作用(DDI)的患病率。方法:于2020年10 - 12月采用横断面普查型设计进行观察性流行病学研究。通过查阅和分析Medscape药物相互作用检查和Micromedex数据库确定药物-药物相互作用。当相互作用可能是致命的和/或需要医疗干预以避免或尽量减少严重的不良反应时,相互作用被分类为严重的,当相互作用可能加剧患者的病情和/或需要改变治疗时,相互作用被分类为中度。结果:在研究期间肿瘤服务的194例患者中,共有74例患者被纳入研究。共发现24例(32.4%)ddi,其中21例(87.5%)为重度危险,3例(12.5%)为中度危险。根据作用机制,19例(79.1%)为药效学相互作用,5例(20.9%)为药代动力学相互作用。结论:相当比例的静脉化疗患者存在与精神药物相互作用的风险。因此,肿瘤学家必须考虑患者使用的所有精神药物和其他药物,以避免药物相互作用。
{"title":"Potential Drug Interactions Between Psychotropics and Intravenous Chemotherapeutics Used by Patients With Cancer.","authors":"Eric Diego Turossi-Amorim,&nbsp;Bruna Camargo,&nbsp;Diego Zapelini do Nascimento,&nbsp;Fabiana Schuelter-Trevisol","doi":"10.1177/87551225211073942","DOIUrl":"https://doi.org/10.1177/87551225211073942","url":null,"abstract":"<p><p><b>Introduction:</b> Patients undergoing cancer treatment usually have comorbidities, and psychiatric disorders are commonly seen in these patients. For the treatment of these psychiatric disorders, the use of psychotropic drugs is common, turning these patients susceptible to untoward drug interactions. Therefore, the aim of this study was to estimate the prevalence of clinically relevant drug-drug interactions (DDI) between chemotherapeutic and psychotropic agents in patients with cancer treated at an oncology service in southern Brazil. <b>Methods:</b> An observational epidemiological study with a cross-sectional census-type design was carried out between October and December 2020. The drug-drug interactions were identified through consultation and analysis of the Medscape Drug Interaction Check and Micromedex databases. The interactions were classified as major, when the interaction can be fatal and/or require medical intervention to avoid or minimize serious adverse effects and moderate, when the interaction can exacerbate the patient's condition and/or requires changes in therapy. <b>Results:</b> A total of 74 patients was included in the study among the 194 patients seen in the oncology service during the period studied. A total of 24 (32.4%) DDIs were found, 21 (87.5%) of which were classified as being of major risk and 3 (12.5%) as moderate risk. According to the mechanism of action, 19 (79.1%) were classified as pharmacodynamic interactions and 5 (20.9%) as pharmacokinetic interactions. <b>Conclusion:</b> It was shown that a considerable percentage of patients undergoing intravenous chemotherapy are at risk of pharmacological interaction with psychotropic drugs. Thus, it is essential that the oncologist considers all psychotropic drugs and other drugs used by patients in order to avoid drug-drug interactions.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116124/pdf/10.1177_87551225211073942.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10799021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Evaluation of Monoclonal Antibodies in Preventing Hospitalizations, Emergency Department Visits, and Mortality in High-Risk COVID-19 Patients. 单克隆抗体在预防COVID-19高危患者住院、急诊和死亡率中的作用
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-01 DOI: 10.1177/87551225221080027
Ashlee N Milam, Diana T Doan, Darrell T Childress, Spencer H Durham

Background: The coronavirus disease 2019 (COVID-19) is a novel coronavirus that has caused an unprecedented global pandemic, with few treatment options currently available. Neutralizing monoclonal antibodies (mAbs) are a promising treatment approach to reduce hospitalizations in high-risk patients with mild-to-moderate COVID-19 infections.

Objective: The primary objective is to compare hospitalization rates of high-risk patients who tested positive for COVID-19 within 28 days between those who received mAb infusions versus those who did not. Secondary objectives were emergency department (ED) visits and mortality within 28 days of a positive test.

Methods: This single-center, institutional review board-approved, retrospective, observational cohort study included patients aged 19 years and older who tested positive for COVID-19 between December 2, 2020 and February 28, 2021. Patients who received the mAbs bamlanivimab or casirivimab/imdevimab were compared with patients who did not receive mAb infusions to examine hospitalization rates, ED visits, and mortality within 28 days of the positive COVID-19 test.

Results: A total of 2780 patients were evaluated for inclusion using electronic chart review via Cerner. Of the 1612 patients who met inclusion criteria, 568 received an mAb infusion (mAb group) and 1044 did not (non-mAb group). Baseline characteristics were similar between the 2 groups. Of the patients in the mAb group, 34 (6%) were hospitalized versus 397 (38%) in the non-mAb group. Patients with ED visits included 111 (20%) and 672 (64%) in the mAb and non-mAb groups, respectively. Finally, 5 patients in the mAb group experienced mortality (0.9%) versus 83 (8%) in the non-mAb group. Each endpoint achieved statistical significance with a P value of <0.0001.

Conclusion: Monoclonal antibody infusions are effective in preventing hospitalization, ED visits, and mortality in high-risk patients with mild-to-moderate COVID-19.

背景:2019冠状病毒病(COVID-19)是一种新型冠状病毒,引起了前所未有的全球大流行,目前可用的治疗方案很少。中和性单克隆抗体(mab)是一种很有前景的治疗方法,可减少轻中度COVID-19感染高危患者的住院率。目的:主要目的是比较接受单抗输注与未接受单抗输注的高危患者在28天内COVID-19检测呈阳性的住院率。次要目标是急诊科(ED)的访问量和28天内阳性检测的死亡率。方法:这项经机构审查委员会批准的单中心回顾性观察性队列研究纳入了2020年12月2日至2021年2月28日期间COVID-19检测呈阳性的19岁及以上患者。将接受单抗治疗的患者与未接受单抗输注的患者进行比较,以检查COVID-19检测阳性后28天内的住院率、急诊科就诊率和死亡率。结果:共有2780例患者通过Cerner的电子病历评估纳入。在符合纳入标准的1612例患者中,568例接受了单抗输注(单抗组),1044例没有(非单抗组)。两组患者的基线特征相似。在单抗组中,34名(6%)患者住院,而非单抗组中有397名(38%)患者住院。单抗组和非单抗组ED就诊患者分别为111例(20%)和672例(64%)。最后,单抗组中有5例患者出现死亡率(0.9%),而非单抗组中有83例(8%)。结论:单克隆抗体输注可有效预防轻、中度高危患者住院、急诊、死亡率。
{"title":"Evaluation of Monoclonal Antibodies in Preventing Hospitalizations, Emergency Department Visits, and Mortality in High-Risk COVID-19 Patients.","authors":"Ashlee N Milam,&nbsp;Diana T Doan,&nbsp;Darrell T Childress,&nbsp;Spencer H Durham","doi":"10.1177/87551225221080027","DOIUrl":"https://doi.org/10.1177/87551225221080027","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus disease 2019 (COVID-19) is a novel coronavirus that has caused an unprecedented global pandemic, with few treatment options currently available. Neutralizing monoclonal antibodies (mAbs) are a promising treatment approach to reduce hospitalizations in high-risk patients with mild-to-moderate COVID-19 infections.</p><p><strong>Objective: </strong>The primary objective is to compare hospitalization rates of high-risk patients who tested positive for COVID-19 within 28 days between those who received mAb infusions versus those who did not. Secondary objectives were emergency department (ED) visits and mortality within 28 days of a positive test.</p><p><strong>Methods: </strong>This single-center, institutional review board-approved, retrospective, observational cohort study included patients aged 19 years and older who tested positive for COVID-19 between December 2, 2020 and February 28, 2021. Patients who received the mAbs bamlanivimab or casirivimab/imdevimab were compared with patients who did not receive mAb infusions to examine hospitalization rates, ED visits, and mortality within 28 days of the positive COVID-19 test.</p><p><strong>Results: </strong>A total of 2780 patients were evaluated for inclusion using electronic chart review via Cerner. Of the 1612 patients who met inclusion criteria, 568 received an mAb infusion (mAb group) and 1044 did not (non-mAb group). Baseline characteristics were similar between the 2 groups. Of the patients in the mAb group, 34 (6%) were hospitalized versus 397 (38%) in the non-mAb group. Patients with ED visits included 111 (20%) and 672 (64%) in the mAb and non-mAb groups, respectively. Finally, 5 patients in the mAb group experienced mortality (0.9%) versus 83 (8%) in the non-mAb group. Each endpoint achieved statistical significance with a <i>P</i> value of <0.0001.</p><p><strong>Conclusion: </strong>Monoclonal antibody infusions are effective in preventing hospitalization, ED visits, and mortality in high-risk patients with mild-to-moderate COVID-19.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116122/pdf/10.1177_87551225221080027.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10252886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Evaluation of Current Hazardous Drug Exposure Control in Community Pharmacy. 社区药房危险药物暴露控制现状评价。
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-01 DOI: 10.1177/87551225211072743
John Papastergiou, Tom Smiley

Purpose: To evaluate effectiveness of current hazardous drug exposure control practices in community pharmacies through identification of commonly contaminated surfaces. We also assessed the decontamination effectiveness of 5 different cleaning agents. Methods: This study was prospective and nonrandomized and conducted in 2 phases. In phase 1, 15 common areas used in the dispensing process were tested at each of 4 pharmacies in Toronto Ontario, Canada. Testing was conducted using the BD® HD Check System, a rapid, point-of-care, hazardous drug detection system that is able to identify contamination with methotrexate (MTX) and cyclophosphamide (CYP) and doxorubicin. In phase 2, 5 different cleaning agents (70% isopropyl alcohol, Lysol® spray, Ecolab® retail multiquat sanitizer, Ecolab retail multisurface and glass cleaner with peroxide, and Ecolab QSR heavy-duty degreaser) were tested for their ability to eliminate contamination. Results: All 4 pharmacies tested positive for contamination with MTX (25.8% of surfaces). Contamination with CYP was less frequent, with only 3 sites and 18.2% of surfaces testing positive. Of the 5 cleaning agents tested, only Ecolab QSR heavy-duty degreaser was able to eliminate contamination with MTX. None of the agents were successful against CYP. Conclusions: The results illustrate an unacceptable prevalence of hazardous drug contamination in community pharmacy settings. The BD HD Check System can serve to rapidly detect common high-risk areas for surface contamination. Decontamination protocols against MTX may include Ecolab QSR heavy-duty degreaser. Novel agents must be identified to remove contamination caused by CYP.

目的:通过识别常见污染表面,评价当前社区药房危险药物暴露控制措施的有效性。我们还评估了5种不同清洗剂的去污效果。方法:本研究为前瞻性非随机研究,分2期进行。在第一阶段,在加拿大安大略省多伦多市的4家药房分别对配药过程中使用的15个公共区域进行了测试。测试使用BD®HD检查系统进行,这是一种快速、即时、危险药物检测系统,能够识别甲氨蝶呤(MTX)、环磷酰胺(CYP)和阿霉素的污染。在第2阶段,测试了5种不同的清洗剂(70%异丙醇、来索尔®喷雾、艺康®零售多季消毒液、艺康®零售多表面和含过氧化氢的玻璃清洗剂以及艺康QSR重型脱脂剂)消除污染的能力。结果:4家药店均检测出甲氨蝶呤污染阳性(25.8%)。CYP污染较少,只有3个位点和18.2%的表面检测呈阳性。在测试的5种清洗剂中,只有艺康QSR重型脱脂剂能够消除MTX的污染。没有一种药物对CYP有效。结论:结果表明,在社区药房环境中,危险药物污染的流行程度是不可接受的。屋宇署检查系统可迅速侦测常见的表面污染高危区域。针对MTX的净化方案可能包括艺康QSR重型脱脂剂。必须确定新的药剂来去除CYP引起的污染。
{"title":"Evaluation of Current Hazardous Drug Exposure Control in Community Pharmacy.","authors":"John Papastergiou,&nbsp;Tom Smiley","doi":"10.1177/87551225211072743","DOIUrl":"https://doi.org/10.1177/87551225211072743","url":null,"abstract":"<p><p><b>Purpose</b>: To evaluate effectiveness of current hazardous drug exposure control practices in community pharmacies through identification of commonly contaminated surfaces. We also assessed the decontamination effectiveness of 5 different cleaning agents. <b>Methods</b>: This study was prospective and nonrandomized and conducted in 2 phases. In phase 1, 15 common areas used in the dispensing process were tested at each of 4 pharmacies in Toronto Ontario, Canada. Testing was conducted using the BD<sup>®</sup> HD Check System, a rapid, point-of-care, hazardous drug detection system that is able to identify contamination with methotrexate (MTX) and cyclophosphamide (CYP) and doxorubicin. In phase 2, 5 different cleaning agents (70% isopropyl alcohol, Lysol<sup>®</sup> spray, Ecolab<sup>®</sup> retail multiquat sanitizer, Ecolab retail multisurface and glass cleaner with peroxide, and Ecolab QSR heavy-duty degreaser) were tested for their ability to eliminate contamination. <b>Results</b>: All 4 pharmacies tested positive for contamination with MTX (25.8% of surfaces). Contamination with CYP was less frequent, with only 3 sites and 18.2% of surfaces testing positive. Of the 5 cleaning agents tested, only Ecolab QSR heavy-duty degreaser was able to eliminate contamination with MTX. None of the agents were successful against CYP. <b>Conclusions:</b> The results illustrate an unacceptable prevalence of hazardous drug contamination in community pharmacy settings. The BD HD Check System can serve to rapidly detect common high-risk areas for surface contamination. Decontamination protocols against MTX may include Ecolab QSR heavy-duty degreaser. Novel agents must be identified to remove contamination caused by CYP.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116126/pdf/10.1177_87551225211072743.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10252891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of Community Pharmacy Competencies. 社区药学能力的发展。
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-01 DOI: 10.1177/87551225221081370
Pantira Parinyarux, Teerapon Dhippayom, Payom Wongpoowarak, Nantawarn Kitikannakorn

Objective: This study aimed to develop a consensus statement of competencies for community pharmacists in Thailand.

Methods: A 2-round modified Delphi process was used to develop consensus among a panel of community pharmacy experts. A total of 18 experts from 6 stakeholders represented a panel of each pharmacy organization in Thailand. In the first experts were asked to rate their degree of agreement on whether a competency was essential using a 7-point Likert scale (1 = "not essential competency" to 7 = "the most essential competency"). Also, in the second round, they were asked to rate the competencies from a scale of "must be included" to "must be excluded." Competencies considered "must be excluded" by a consensus of 80% or more of experts were removed from the community pharmacy competency list.

Results: Nearly half the experts had experience in their position for more than 10 years. The expert panels were typically committee members of the Community Pharmacy Association (Thailand) and community pharmacy clerkship preceptors (29.4% and 23.5%, respectively). The number of community pharmacy competencies on the initial list was 55 competencies. None of them was eliminated after the first round. Of 55 competencies, 11 were eliminated after the second round. The final list of competency statements was 44 competencies divided into 4 domains: personal competencies, pharmacy professional competencies, patient care competencies, and management competencies.

Conclusion: Community pharmacy competencies include having a positive attitude and being accountable for individual patient care, providing disease prevention and health promotion, and addressing morality and ethics in business.

目的:本研究旨在制定泰国社区药剂师能力的共识声明。方法:采用2轮修正德尔菲法,在社区药学专家小组中形成共识。来自6个利益攸关方的18名专家代表了泰国各药房组织的一个小组。在第一阶段,专家们被要求用7分李克特量表(1 =“非基本能力”到7 =“最基本能力”)来评价他们对一项能力是否必要的同意程度。此外,在第二轮中,他们被要求从“必须包括”到“必须排除”的范围内对能力进行评级。经80%或以上专家一致认为“必须排除”的能力从社区药房能力清单中删除。结果:近半数专家在同一岗位工作10年以上。专家小组通常是社区药房协会(泰国)的委员会成员和社区药房见习教师(分别为29.4%和23.5%)。最初列表中社区药房胜任力的数量为55个。他们都没有在第一轮后被淘汰。在55项竞争中,有11项在第二轮之后被淘汰。最终的胜任力表共有44项胜任力,分为4个领域:个人胜任力、药学专业胜任力、患者护理胜任力和管理胜任力。结论:社区药房的能力包括积极的态度和对个人病人护理负责,提供疾病预防和健康促进,以及处理商业道德和伦理问题。
{"title":"Development of Community Pharmacy Competencies.","authors":"Pantira Parinyarux,&nbsp;Teerapon Dhippayom,&nbsp;Payom Wongpoowarak,&nbsp;Nantawarn Kitikannakorn","doi":"10.1177/87551225221081370","DOIUrl":"https://doi.org/10.1177/87551225221081370","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to develop a consensus statement of competencies for community pharmacists in Thailand.</p><p><strong>Methods: </strong>A 2-round modified Delphi process was used to develop consensus among a panel of community pharmacy experts. A total of 18 experts from 6 stakeholders represented a panel of each pharmacy organization in Thailand. In the first experts were asked to rate their degree of agreement on whether a competency was essential using a 7-point Likert scale (1 = \"not essential competency\" to 7 = \"the most essential competency\"). Also, in the second round, they were asked to rate the competencies from a scale of \"must be included\" to \"must be excluded.\" Competencies considered \"must be excluded\" by a consensus of 80% or more of experts were removed from the community pharmacy competency list.</p><p><strong>Results: </strong>Nearly half the experts had experience in their position for more than 10 years. The expert panels were typically committee members of the Community Pharmacy Association (Thailand) and community pharmacy clerkship preceptors (29.4% and 23.5%, respectively). The number of community pharmacy competencies on the initial list was 55 competencies. None of them was eliminated after the first round. Of 55 competencies, 11 were eliminated after the second round. The final list of competency statements was 44 competencies divided into 4 domains: personal competencies, pharmacy professional competencies, patient care competencies, and management competencies.</p><p><strong>Conclusion: </strong>Community pharmacy competencies include having a positive attitude and being accountable for individual patient care, providing disease prevention and health promotion, and addressing morality and ethics in business.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116120/pdf/10.1177_87551225221081370.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10252893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Journal of Pharmacy Technology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1